New Jersey-based drug delivery company Vyteris has merged with MediSync BioServices, a company focused on consolidating CROs.  MediSync has become a fully-owned subsidiary of Vyteris.

Haro Hartounian, CEO at Vyteris, said: “MediSync's current and possible future operations intend to potentially serve a growing demand for outsourced clinical research and related services as drug and medical device developers may be attracted to the efficiency and flexibility.”